

**Publikationer (originale meddelelser):**  
**H index: 40 (Google scholar)**

1

Nybo Rasmussen S, Iversen P. The extravascular pool of albumin in the non-diuretic rat kidney estimated by means of radioactive tracers and quantitative immunochemistry. *Plügers Arch* 363: 239-244, 1976.

2

Klarskov P, Møller I, Iversen P, Iversen Hansen R. Urethral pressure profile and retrograde urethrography in diagnosis of urethral strictures. *Urol Int* 34: 161-166, 1979.

3

Mosdal C, Iversen P, Iversen Hansen R. Bladder neuropathy in lumbar disc disease. *Acta Neurochir* 46: 281-286, 1979.

4

Iversen Hansen R, Iversen P. Bladder explosion during uninterrupted transurethral resection of the prostate. *Scand J Urol Nephrol* 13: 211-212, 1979.

5

Iversen P, Nielsen OS, Vergin H, Madsen PO. Metioprim-sulphadiazine distribution in the canine prostate. *The Prostate* 2: 327-335, 1981.

6

Madsen PO, Iversen P. Cefotaxime and cefazolin in the treatment of complicated urinary tract infections: A comparative study. *Clinical Therapeutics* 4: 7-11, 1981.

7

Bruskewitz RC, Iversen P, Madsen PO. Urodynamics in the evaluation of benign prostatic hyperplasia: Predictive value. *Surgical Forum* 32: 630-632, 1981.

8

Iversen P, Madsen PO. Complicated urinary tract infections treated with cefuroxime or cefazolin: A comparative study. *Clinical Therapeutics* 4: 302-306, 1981.

9

Iversen P, Madsen PO. Bacterial adherence to urothelium following bladder irrigation in the rat. *Infection* 10: 116-119, 1982.

10

Nielsen OS, Iversen O, Vergin H, Madsen PO. Tetroxoprim-sulphadiazine distribution in canine prostate. *Acta Pharmacol et Toxicol* 51: 446-449, 1982.

11

Iversen P, Madsen PO. Short term prophylaxis with cephalosporins in transurethral surgery. *Clinical Therapeutics* 5: 58-66, 1982.

12

Iversen P, Bruskewitz RC, Madsen PO. The value of post void residual urine determination in the evaluation of prostatism. *Urology* 20: 602-604, 1982.

**Publikationer (originale meddelelser) fortsat:**

13

Nielsen OS, Iversen P, Vergin H, Madsen PO. Tetroxoprim-sulphadiazine distribution in canine prostate.

J Antimicrob Chemother 9; 240-242, 1982

14

Iversen P, Iversen Hansen R. Akut abdomen forårsaget af intraperitoneal blæreruptur. Ugeskr Læger 141: 1094-1095, 1982.

15

Iversen P, Madsen PO. Distribution of Ro 10-5970, a new trimethoprim analogue, in the canine prostate. Current Chemotherapy and Immunotherapy 2: 943, 1982.

16

Iversen P, Madsen PO. Trimethoprim, metioprim, tetroxoprim, and Ro 10-5970 in canine bone. Acta Pharmacol et Toxicol 51: 446-449, 1982.

17

Iversen P, Nielsen SO, Jensen KM-E, Madsen PO. Comparison of concentrations of Rifampin and a new rifamycin derivative, DL 473, in canine bone.

Antimicrobial Agents and Chemotherapy 23: 338-340, 1983.

18

Iversen P, Bruskewitz RC, Jensen KM-E, Madsen PO.

Transurethral prostatic resection in the treatment of prostatism with high urinary flow.

J Urol 129: 995-997, 1983.

19

Iversen P, Jensen KM-E, Bruskewitz RC, Madsen PO. Intravesical pressure measurement in urodynamic investigation employing a modified "J" nephrostomy catheter.

Urology 21: 550-552, 1983.

20

Jensen KM-E, Bruskewitz RC, Iversen P, Madsen PO.

Predictive value of voiding pressures in benign prostatic hyperplasia.

Neurourology and Urodynamics 2: 117-125, 1983.

21

Bruskewitz RC, Jensen KM-E, Iversen P, Madsen PO.

The relevance of minimum urethral resistance in prostatism.

J Urol 129: 769-771, 1983.

22

Jensen KM-E, Bruskewitz RC, Iversen P, Madsen PO.

Abdominal straining in benign prostatic hyperplasia. J Urol 129: 44-47, 1983.

23

Madsen PO, Jensen KM-E, Iversen P. Chronic bacterial prostatitis: Theoretical and experimental considerations. Urol Res 11: 1-5, 1983.

24

Jensen KM-E, Bruskewitz RC, Iversen P, Madsen PO. Significance of prostatic weight in prostatism. Urol Int 38: 173-178, 1983.

25

Jensen KM-E, Bruskewitz RC, Iversen P, Madsen PO. Spontaneous uroflowmetry in prostatism. Urology 24: 403-409, 1984.

**Publikationer (originale meddelelser) fortsat:**

26

Iversen P, Vergin H, Madsen PO. Renal handling and lymph concentrations of tetroxoprim and metioprim: An experimental study in dogs.

J Urol 132: 362-364, 1984.

27

Frimodt-Møller PC, Bruskewitz RC, Jensen KM-E, Iversen P, Madsen PO. Analysis of presenting symptoms in prostatism.

J Urol 132, 272-276, 1984.

28

Dørflinger T, Frimodt-Møller PC, Bruskewitz RC, Jensen KM-E, Iversen P, Madsen PO. The significance of uninhibited detrusor contractions in prostatism.

J Urol 133: 819-821, 1985.

29

Dørflinger T, Bruskewitz RC, Jensen KM-E, Iversen P, Madsen PO. Predictive value of low maximum flow rate in benign prostatic hyperplasia.

Urology 27: 569-573, 1986.

30

Kjær L, Thomsen C, Iversen P, Henriksen O. In vivo estimation of relaxation processes in benign hyperplasia and carcinoma of the prostate gland by magnetic resonance imaging.

Magnetic Resonance Imaging 5: 23-30, 1987.

31

Iversen P, Kjær L, Thomsen C, Henriksen O. Magnetic resonance imaging of the prostate.

Scand J Urol Nephrol, suppl 104: 41-45, 1987.

32

Iversen P, Kjær L, Thomsen C, Henriksen O. Magnetic resonance imaging of the prostate.

Scand J Urol Nephrol, suppl 107: 14-18, 1988.

(Almost identical to paper above)

33

Kjær M, Iversen P, Hvidt V, Bruun E, Skaarup P,

Bech Hansen J, Wolf H, Frederiksen PL. A randomized trial of postoperative radiotherapy versus observation in stage II and III renal adenocarcinoma. A study by the Copenhagen Renal Cancer Study Group.

Scand J Urol Nephrol 21: 285-289, 1987.

34

Jakobsen H, Nordling J, Munck O, Iversen P, Nielsen SL, Holm HH. Sensitivity of <sup>131</sup>I-Hippuran diuresis renography and pressure flow study (Whitaker test) in upper urinary tract obstruction. Urol Int 43: 89-92, 1988.

35

Møller S, Iversen P. Svær toksisk hepatitis under flutamid (Eulexin) behandling.

Ugeskr Læger 151: 173-174, 1989.

**Publikationer (originale meddelelser) fortsat:**

36

Iversen P, Rose C, Stage JG, Iversen H-G, Hansen RI, Hvidt V, Mogensen P, Pedersen T, Hansen JB and Copenhagen Prostate Cancer Group: LHRH analogue as a depot preparation (Zoladex) in the treatment of advanced carcinoma of the prostate followed by orchiectomy as a second line therapy. A phase II study.

Scand J Urol Nephrol 23: 177-183, 1989.

37

Iversen P, Bak M, Juul N, Laursen F, Nielsen L, Rasmussen F, Torp-Pedersen S, von der Maase H, Holm HH. Ultrasonically guided 125-I seed implantation combined with external radiation in the management of localized prostatic carcinoma.

Urology 34: 181-186, 1989.

38

Iversen P, Torp-Pedersen ST. Screening for carcinoma of the prostate. Sound prophylaxis or harmful intervention?

Current Opinion in Radiology 1: 255-263, 1989.

39

Møller S, Iversen P, Franzmann M-B. Flutamide-induced liver failure.

Hepatology 10: 346-349, 1990.

40

Iversen P, Christensen MG, Friis E, Hornbøl P, Hvidt V, Iversen H-G, Klarskov P, Krarup T, Lund F, Mogensen P, Pedersen T, Rasmussen F, Rose C, Skaarup P, Wolf H. A phase III trial of zoladex and flutamide versus orchiectomy in the treatment of patients with advanced carcinoma of the prostate. Cancer 66: 1058-1066, 1990.

41

Suciu S, Sylvester R, Christensen I, Iversen P, Denis L.

Comparability of EORTC and DAPROCA studies in advanced prostatic cancer.

Cancer 66: 1029-1034, 1990.

42

Iversen P, Suciu S, Christensen I, Sylvester R, Denis L. Zoladex and flutamide versus orchiectomy in the treatment of advanced prostatic cancer: A combined analysis of two European studies - EORTC 30853 and DAPROCA 86.

Cancer 66: 1067-1073, 1990.

43

Iversen P, Torp-Pedersen ST. Screening for prostatic cancer -investigational models.

Acta Oncologica 30: 281-284, 1991.

44

Iversen P, and the DAPROCA group. Zoladex plus Flutamide versus orchidectomy for advanced prostatic cancer.

European Urology 18 (S3): 41-44, 1990.

45

Iversen P, Rasmussen F, Holm HH. Long term results of ultrasonically guided implantation of 125-iodine seeds combined with external irradiation in the treatment of localized prostatic cancer. Scand J Urol Nephrol suppl 138: 109-115, 1991.

**Publikationer (originale meddelelser) fortsat:**

46

Ovesen H, Iversen P, Beier-Holgersen R, Hald T, Rasmussen F, Steven K. Extraperitoneal pelviscopy in staging of bladder carcinoma and detection of pelvic lymph node metastasis. *Scan J Urol Nephrol* 27: 211-214, 1993

47

Suciu S, Sylvester R, Iversen P, Christensen IJ, Denis L. Comparability of prostate cancer trials. *Cancer* 72: 3841-3846, 1993

48

Iversen P, Rasmussen F, Klarskov P, Christensen IJ, and DAPROCA. Long-term results of Danish Prostatic Cancer Group Trial 86. Goserelin acetate plus flutamide versus orchiectomy in advanced prostate cancer. *Cancer* 72: 3851-3854, 1993.

49

Jonsson PM, Danneskiold-Samsøe B, Heggstad T, Iversen P, Leisti S. Management of early prostatic cancer in the Nordic Countries: Variations in clinical policies and physicians attitudes toward radical treatment. A Nordic Evaluation of Medical Technology (NEMT) survey. *International Journal of Technology Assessment in Health Care* 11: 66-78, 1995.

50

Rudnicki M, Jensen LT, Iversen P. Collagen derived serum markers in carcinoma of the prostate. *Scand J Urol Nephrol*, 29; 317-321, 1995

51

Iversen P, Rasmussen F, Christensen I. Serum testosterone as prognostic factor in patients with advanced prostatic cancer. *Scand J Urol Nephrol, Suppl.* 157; 41-47, 1994.

52

Iversen P, on behalf of the International Casodex Investigators. Update of Clinical trials with the new anti-androgen, Casodex (ICI 176,334). *European Urology*, 26(suppl 1): 1-9, 1994.

53

Iversen P, Tveter K, Varenhorst E, Scandinavian Casodex Cooperative Group. Randomised Study of Casodex 50 mg monotherapy versus orchidectomy in the treatment of metastatic prostate cancer. *Scand J Urol Nephrol* 30; 93-98, 1996.

54

Iversen P, Madsen PO, Corle DK. Radical prostatectomy versus expectant treatment for early carcinoma of the prostate. Twenty-three year follow-up of a prospective randomized study. *Scand J Urol Nephrol, Suppl* 172; 65-72, 1995

55

Iversen P, Rasmussen F, Asmussen C, Christensen IJ, Eickhoff J, Klarskov P, Larsen E, Mogensen P, Mommsen S, Rasmussen F, Rosenkilde P. Estramustine phosphate vs. placebo as second line treatment after orchiectomy in patients with metastatic prostate cancer. DAPROCA Study 9002. *Journal of Urology* 157; 929-934, 1997.

56

Tyrrell CJ, Kaisary AV, Iversen P, Anderson JB, Baert L, Tammela T, Chamberlain M, Webster A, Blackledge G. A randomised comparison of 'Casodex' (Bicalutamide) 150 mg monotherapy versus castration in the treatment of metastatic and locally advanced prostate cancer. *European Urology*, 33; 447-456, 1998.

**Publikationer (originale meddelelser) fortsat:**

57

Andersen BR, Knorr UBS, Brasso K, Iversen P. Prostata specifikt antigen, sure fosfataser og rektaleksploration i diagnostik af cancer prostatae. Ugeskrift for Læger 159; 2538-2542, 1997.

58

Brasso K, Sønksen J, Sommer P, Ødum L, Biering-Sørensen F, Iversen P, Kristensen JK. Seminal plasma PSA in spinal cord injured men: a preliminary report. Spinal Cord 36; 771-773, 1998.

59

Brasso K, Friis S, Kjær SK, Iversen P. Cancer prostatae hos mænd under 65 år. Forekomst og behov for udredning. Ugeskrift for Læger 159; 2543-2545, 1997

60

Brasso K, Friis S, Kjær SK, Jørgensen T, Iversen P. Prostate cancer in Denmark. A 50-year population-based study. Urology 51; 590-594, 1998

61

Brasso K, Friis S, Juel K, Jørgensen T, Iversen P. Lokaliseret cancer prostatae. Overlevelse og tab af leveår. Ugeskrift for Læger 160; 4517-4520, 1998.

62

Iversen P, Tyrrell CJ, Kaisary AV, Anderson JB, Baert L, Tammela T, Chamberlain M, Carroll K, Gotting-Smith K, Blackledge G. "Casodex" (Bicalutamide) 150 mg monotherapy compared with castration in patients with previously untreated non-metastatic prostate cancer: Results from two multicenter randomized trials at a median follow-up of 4 years. Urology 51; 389-396, 1998.

63

Brasso K, Friis S, Juel K, Jørgensen T, Iversen P. Mortality in patients with clinically localized prostate cancer treated with observation for 10 years or longer: A population based registry study. Journal of Urology 1999; 161: 524-528.

64

Levi N, Sønksen J, Iversen P, Helgstrand U. Rupture of an iliac artery aneurism into ureter. Eur J Vasc and Endovasc Surg. 1999; 17: 264-265.

65

Brasso K, Iversen P. Prostate cancer in Denmark. Incidence, morbidity, and mortality. Scand J Urol Nephrol 1999; 33 (suppl 203): 29-33.

66

Brasso K, Friis S, Juel K, Jørgensen T, Iversen P. The need for hospital care of patients with clinically localized prostate cancer managed by noncurative intent: A population based registry study. Journal of Urology 2000; 163: 1150-1154.

67

Brasso K, Friis S, Juel K, Jørgensen T, Iversen P. Morbidity in patients with clinically localized prostate cancer managed with non-curative intent. A population-based case-control study. Prostate Cancer and Prostatic Diseases. 1999; 2: 253-256.

68

Hedlund PO, Ala-Opas M, Brekkan E, Damber JE, Damber L, Hagerman I, Haukaas S, Henriksson P, Iversen P, Pousette Å, Rasmussen F, Salo J, Vaage S, Varenhorst E. Parenteral oestrogen versus combined androgen blockade in the treatment of advanced prostatic carcinoma. Effects on overall survival and cardiovascular mortality. Urology 2000; 55: 328-333.

**Publikationer (originale meddelelser) fortsat:**

69

See WA, McLeod D, Iversen P, Wirth M. The bicalutamide early prostate cancer program: Demography. *Urologic Oncology* 2001; 6(2): 43-47.

70

Brasso K, Ingelholm P, Iversen P. Radikal prostatektomi. De første 50 konsekutive patienter opereret på Rigshospitalet. *Ugeskrift for Læger* 2001; 163: 5669-5673.

71

Iversen P, Tyrrell CT, Kaisary AV, Anderson JB, Van Poppel H, Tammela T, Chamberlain M, Carroll K, Melezinek I. Bicalutamide ('Casodex') 150 mg monotherapy compared with castration in patients with non-metastatic locally advanced prostate cancer: 6.3 years of follow-up. *Journal of Urology* 2000; 164: 1579-1582.

72

Tyrrell CT, Blake GM, Iversen P, Kaisary AV, Melezinek I. The non-steroidal antiandrogen, bicalutamide ("Casodex"), may preserve bone mineral density as compared with castration; results of a preliminary study. *World Journal of Urology* 2003; 21: 37-42.

73

Brasso K, Friis S, Juel K, Jørgensen T, Iversen P. Sygelighed blandt patienter med klinisk lokaliseret prostatacancer. Et registerbaseret case-kontrol studie. *Ugeskrift for Læger* 2001; 163: 5673-5676.

74

See WA, Wirth M, McLeod DG, Iversen P, Klimberg I, Gleason D, Chodak G, Montie J, Tyrrell C, Wallace M, Delaere K, Vaage S, Tammela T, Lukkarinen O, Persson B-E, Carroll K, Kolvenbag GJCM. on behalf of the Casodex Early Prostate Cancer Trialist Group. Bicalutamide ("Casodex") 150 mg as immediate therapy either alone or as adjuvant to standard care in patients with localized or locally advanced prostate cancer: First analysis of the Early Prostate Cancer program. *J Urol* 2002; 168 (2): 429-435

75

Iversen P, Tammela TLJ, Vaage S, Lukkarinen O, Lodding P, Bull-Njaa T, Viitanen J, Hoisæter P, Lundmo P, Rasmussen F, Johansson J-E, Persson B-E, Carroll K, SPCG-6 study group. A randomised comparison of bicalutamide (Casodex) 150 mg versus placebo as immediate therapy either alone or as adjuvant to standard care for early non-metastatic prostate cancer. First report from the Scandinavian Prostatic Cancer Group study 6. *Eur Urol* 2002; 42: 204-211.

76

Payne H, Tyrrell CJ, See WA, McLeod DG, Wirth MP, Iversen P, Garside L. Bicalutamide 150 mg as adjuvant to radiotherapy significantly increases progression-free survival in early prostate cancer. *Int J Radiat Oncol Biol Phys* 2003; 57 (2 suppl): 173-174.

77

Wirth M, Iversen P, McLeod D, See W. Immediate therapy in early prostate cancer: Results from the bicalutamide (Casodex) EPC Programme. *Eur Urol* 2002; (suppl 1): 20-25.

78

See W, Iversen P, Wirth M, McLeod D, Garside L, Morris T. Immediate treatment with bicalutamide 150 mg as adjuvant therapy significantly reduces the risk of PSA progression in early prostate cancer. *Eur Urol* 2003; 44: 512-518

**Publikationer (originale meddelelser) fortsat:**

79

Usher PA, Thomsen OF, Iversen P, Johnsen M, Br nner N, Hoyer-Hansen G, Andreasen P, Dan  K, Nielsen BS. Expression of urokinase plasminogen activator, its receptor and type-1 inhibitor in malignant and benign prostate tissue. *Int J Cancer* 2005; 113(6): 870-880.

80

Hedlund PO, Ala-Opas M, Brekkan E, Damber L-E, Damber L, Hagerman I, Haukaas S, Henriksson P, Iversen P, Pousette  , Rasmussen F, Salo J, Vaage S, Varenhorst E and SPCG-5 group. Parenteral estrogen versus combined androgen androgen deprivation in the treatment of metastatic prostatic cancer – Scandinavian Prostatic Cancer Group (SPCG) study no 5. *Scand J Urol Nephrol* 2002; 36: 405-413, 2002.

81

Iversen P, Wirth M, See W, McLeod D, Klimberg I, Gleason D, Chodak G, Montie J, Tyrrell C, Wallace DM, Delaere KP, Lundmo P, Tammela T, Johansson J-E, Morris T, Carroll K. Is the efficacy of hormonal therapy affected by lymph node status? Data from the bicalutamide (Casodex) Early Prostate Cancer Program. *Urology* 2004; 63(5): 928-933

82

Iversen P, Johansson J-E, Lodding P, Lukkarinen O, Lundmo P, Klarskov P, Tammela TLJ, Tastemir I, Morris T, Carroll K. Bicalutamide (150 mg) versus placebo as immediate therapy alone or as adjuvant to therapy with curative intent for early nonmetastatic prostate cancer: 5.3 years median followup from the Scandinavian Prostate Cancer Group Study number 6. *Journal of Urology* 2004; 172:1871-1876

83

Wirth MP, See WA, McLeod DG, Iversen P, Morris T, Carroll K. Bicalutamide 150 mg in addition to standard care in patients with localized or locally advanced prostate cancer: Results from the second analysis of the early prostate cancer program at median followup of 5.4 years. *Journal of Urology* 2004; 172: 1865-1870

84

Stranne J, Hugosson J, Iversen P, Morris T, Lodding P. Inguinal hernia in stage M0 prostate cancer: a comparison of incidence in men treated with and without radical retropubic prostatectomy - an analysis of 1105 patients. *Urology* 2005; 65: 847-851.

85

Tyrrell CJ, Payne H, See WA, McLeod DG, Wirth MP, Iversen P, Armstrong J, Morris C. Bicalutamide ('Casodex') 150 mg as adjuvant to radiotherapy in patients with localised or locally advanced prostate cancer: results from the randomised Early Prostate Cancer Programme. *Radiother Oncol.* 2005 Jul;76(1):4-10.

86

Brasso K, Christensen IJ, Johansen JS, Teisner B, Garner P, Price PA, Iversen P. Prognostic value of serum PINP, bone alkaline phosphatase, CTX-I, and YKL-40 in patients with metastatic prostate carcinoma. *The Prostate* 2006; 66(5): 503-513.

87

Warren KS, Chodak GW, See WA, Iversen P, McLeod D, Wirth M, Morris C, Armstrong J. Are bone scans necessary in men with low prostate specific antigen levels following localized therapy? *Journal of Urology* 2006; 176(1): 70-73.



**Publikationer (originale meddelelser) fortsat:**

88

McLeod DG, Iversen P, See WA, Morris T, Armstrong J, Wirth MP. Bicalutamide 150 mg plus standard care versus standard care alone for early prostate cancer. *British J Urology International* 2006; 97(2): 247-254.

89

Iversen P. The third analysis of the bicalutamide early prostate cancer programme. *British Journal of Urology International* 2006; 97(3): 438-439.

90

Tyrrell CJ, Iversen P, Tammela T, Anderson J, Bjork T, Kaisary AV, Morris T. Tolerability, efficacy and pharmacokinetics of bicalutamide 300 mg, 450 mg or 600 mg as monotherapy for patients with locally advanced or metastatic prostate cancer, compared with castration. *British Journal of Urology International* 2006; 98(3): 563-572.

91

Iversen P, Johansson JE, Lodding P, Kylmala T, Lundmo P, Klarskov P, Tammela TL, Tasdemir I, Morris T, Armstrong J. Bicalutamide 150 mg in addition to standard care for patients with early non-metastatic prostate cancer. Updated results from the Scandinavian Prostate Cancer Group-6 Study after a median follow-up of 7.1 years. *Scand J Urol Nephrol* 2006; 40: 441-452.

92

Brasso K, Ingimarsdottir IJ, Thomassen L, Friis S, Iversen P. Prostatacancer i Danmark 1943-2002. *Ugeskrift for Læger* 2007; 169: 129-132.

93

Johansen JS, Brasso K, Iversen P, Teisner B, Garnerø P, Price PA, Christensen IJ. Changes of biochemical markers of bone turnover and YKL-40 following hormonal treatment for metastatic prostate cancer are related to survival. *Clin Cancer Res* 2007; 13: 3244-3249.

94

Hedlund PO, Damber JE, Hagerman I, Haukaas S, Henriksson P, Iversen P, Johansson R, Klarskov P, Lundbeck F, Rasmussen F, Varenhorst E, Viitanen J and the SPCG-5 Study Group. Parenteral estrogen versus combined androgen deprivation in the treatment of metastatic prostatic cancer: part 2. Final evaluation of the Scandinavian Prostatic Cancer Group (SPCG) Study No. 5. *Scand J Urol Nephrol* 2008; 42: 220-229.

95

Borre M, Iversen P, Bendixen A, Iversen MG, Kehlet H. Organisation og tidlige operationsresultater efter radikal prostatektomi i Danmark 2004 – 2007. *Ugeskrift for Læger* 2008; 170: 2545-2549.

96

Røder MA, Reinhardt S, Brasso K, Iversen P. Prostatacancer med lymfeknudemetastaser. En opfølgning af 59 konsekutive patienter. *Ugeskrift for Læger* 2008; 170: 2554-2558.

97

Nielsen SJ, Iversen P, Rehfeld JF, Jensen HL, Goetze JP. C-type natriuretic peptide in prostate cancer. *APMIS* 2009; 117: 60-67

98

Røder MA, Gruschy L, Brasso K, Iversen P. Tidlige komplikationer efter åben radikal prostatektomi. *Ugeskrift for Læger* 2009; 171: 1492-1496.

**Publikationer (originale meddelelser) fortsat:**

99

Berg KD, Toft BG, Røder MA, Brasso K, Vainer B, Iversen P. Prostate needle biopsies: Interobserver variation and clinical consequences of histopathological re-evaluation. *APMIS* 2011; 119: 239-246

100

Almasi CE, Brasso K, Iversen P, Pappot H, Høyer-Hansen G, Danø K, Christensen IJ. Prognostic and predictive value of intact and cleaved forms of the urokinase plasminogen activator receptor in metastatic prostate cancer. *Prostate* 2011; 71: 899-907

101

Iversen P, McLeod DG, See WA, Morris T, Armstrong J, Wirth M. Antiandrogen monotherapy in patients with localized or locally advanced prostate cancer: Final results from the bicalutamide Early Prostate Cancer Programme at a median follow-up of 9.7 years. *Br J Urol Int* 2010; 105: 1074-81

102

Iversen P, Karup C, van der Meulen E, Tanko LB, Huhtaniemi I. Hot flushes (HF) during androgen deprivation therapy with monthly degarelix or leuprolide. *Prostate Cancer and Prostatic Diseases* 2011; 14: 184-190

103

Røder MA, Berg KD, Gruschy L, Brasso K, Iversen P. First Danish single-institution experience with radical prostatectomy. Biochemical outcome in 1200 consecutive patients. *Prostate Cancer* 2011; 2011: 236357

104

Hedlund PO, Johansson R, Damber JE, Hagerman I, Henriksson P, Iversen P, Klarskov P, Mogensen P, Rasmussen F, Varenhorst E, and the SPCG-5 group. Significance of pretreatment cardiovascular morbidity as a risk factor during treatment with parenteral estrogen or combined androgen deprivation of 915 patients with metastatic prostate cancer. Evaluation of cardiovascular events in a randomised trial. *Scand J Urol Nephrol* 2011; 45: 346-353.

105

Røder MA, Christensen IJ, Berg KD, Gruschy L, Brasso K, Iversen P. Serum testosterone as a predictor of biochemical failure after radical prostatectomy for localized prostate cancer. *BJU Int* 2012; 109: 520-524.

106

Ulmert D, Vickers AJ, Scher H, Becker C, Iversen P, Frankel D, Jensen J-K, Olesen TK, Lilja H. Rapid elimination kinetics of free PSA or human kallikrein-related peptidase 2 after initiation of gonadotropin-releasing hormone-antagonist treatment of prostate cancer: potential for rapid monitoring of treatment responses. *Clin Chem Lab Med* 2012;50(11): 1993-98.

107

Vrang M-L, Røder MA, Vainer B, Christensen IJ, Gruschy L, Brasso K, Iversen P. First Danish experience with radical prostatectomy: Impact of surgical margins on biochemical outcome. *Scand J Urol Nephrol*. 2012; 46(3): 172-79

**Publikationer (originale meddelelser) fortsat:**

108

Berg KD, Toft BG, Røder MA, Brasso K, Vainer B, Iversen P. Is it possible to predict low-volume and insignificant prostate cancer by core needle biopsies? *APMIS*. 2013;121(4):257-65.

109

Damber J-E, Tammela T, Iversen P, Abrahamsson PA, Boccon-Gibod L, Kold Olesen T, van der Meulen E, Persson B-E. The effect of baseline testosterone on the efficacy of degarelix and leuprolide: further insights from a 12-month, comparative, phase III study in prostate cancer patients. *Urology*. 2012 Jul;80(1):174-81.

110

Røder MA, Berg KD, Christensen IJ, Gruschy L, Braso K, Iversen P. Radical prostatectomy in clinically localised high-risk prostate cancer. Outcome of 231 consecutive patients. *Scand J Urol Nephrol* 2013; 47: 19-25.

111

Røder MA, Iversen P. Radikal prostatektomi ved avanceret prostatacancer. *Ugeskrift for Læger* 2012; 174: 3160-61

112

Røder MA, Brasso K, Berg K, Thomsen FB, Gruschy L, Rusch E, Iversen P. Patients undergoing radical prostatectomy have a better survival than the background population  
*Danish Medical Journal* 2013 Apr; 60(4): 1-5

113

Thomsen FB, Berg KD, Hvarness H, Nielsen J, Iversen P. Robot-assisted radical prostatectomy is a safe procedure. *Danish Medical Journal* 2013; 60(9):1-6.

114

Thomsen FB, Røder MA, Hvarness H, Iversen P, Brasso K. Active surveillance can reduce overtreatment in patients with low-risk prostate cancer. *Danish Medical Journal* 2013; 60(2): 1-6. *Dansk resume: Overbehandling af patienter med lavrisikoprostatacancer kan nedbringes ved active surveillance. Ugeskrift for Læger* 2013; 175: 438.

115

Larsen SB, Brasso K, Iversen P, Christensen J, Christiansen M, Carlsson S, Lilja H, Friis S, Tjønneland A, Dalton SO. Baseline prostate-specific antigen measurements and subsequent prostate cancer risk in the Danish Diet, Cancer and Health cohort. *Eur J Cancer* 2013; 49(14): 3041-8.

116

Hvid T, Winding K, Rinnov A, Dejgaard T, Thomsen C, Iversen P, Brasso K, Mikines KJ, van Hall G, Lindegaard B, Solomon TPJ, Pedersen BK. Endurance training improves insulin sensitivity and body composition in prostate cancer patients treated with androgen deprivation therapy. *Endocrine-related Cancer* 2013; 20(5): 621-32.

117

Hvid T, Lindegaard B, Winding K, Iversen P, Brasso K, Mikiness KJ, Solomon TPJ, Pedersen BK. The effect of home-based endurance training on the progression of prostate cancer. *Endocrine-related Cancer*. Submitted

**Publikationer (originale meddelelser) fortsat:**

118

Røder MA, Brasso K, Christensen IJ, Johansen J, Langkilde NC, Hvarness H, Carlsson S, Jakobsen H, Borre M, Iversen P. Survival after radical prostatectomy for clinically localised prostate cancer: A population-based study. *BJU Int.* 2014; 113(4): 541-547

119

Røder MA, Thomsen FB, Christensen IJ, Toft BG, Brasso K, Vainer B, Iversen P. Risk factors associated with positive surgical margins following radical prostatectomy for clinically localized prostate cancer: Can nerve-sparing surgery increase the risk? *Scand J Urol Nephrol* 2014; 48(1): 15-20.

120

Berg K, M. Røder MA, Brasso K, Vainer B, Iversen P.

Primary Gleason pattern in biopsy Gleason score 7 is predictive of adverse histopathological features and biochemical failure following radical prostatectomy  
*Scand J Urology* 2014; 48(2): 168-176

121

Thomsen F, Christensen IJ, Brasso K, Røder MA, Iversen P. Prostate-specific antigen doubling time as a progression criterion in an active surveillance programme for patients with localised prostate cancer. *British J Urol Int.* 2014; 113 (5b): E98-E105

122

Røder MA, Brasso K, Christensen IJ, Johansen J, Langkilde NC, Hvarness H, Carlsson S, Jakobsen H, Borre M, Iversen P. Changes in Preoperative Characteristics in Patients Undergoing Radical Prostatectomy – a 16-year population based study. *Acta Oncologica* 2014;53 (3): 361-367.

123

Thomsen FB, Røder MA, Rathenburg P, Brasso K, Borre M, Iversen P. Enzalutamide treatment in patients with metastatic castration-resistant prostate cancer progressing after chemotherapy and abiraterone acetate. *Scand J Urol.* 2014; 48(3): 268-275

124

Tombal B, Borre M, Rathenburg P, Werbrouck P, Van Poppel H, Heidenreich A, Iversen P, Braeckman J, Heracek J, Baskin-Bey E, Ouatas T, Perabo F, Phung De, Hirmand M, Smith MR. Enzalutamide monotherapy in hormone-naïve prostate cancer: primary analysis of an open-label single-arm, phase 2 study. *Lancet Oncology.* 2014; 15: 592-600.

125

Røder MA, Thomsen FB, Berg KD, Christensen IJ, Brasso K, Vainer B, Iversen P. Risk of biochemical recurrence and positive surgical margins in patients with pT2 prostate cancer undergoing radical prostatectomy. Impact of nerve-sparing surgery. *J Surg Oncol.* 2014;109(2): 132-138.

**Publikationer (originale meddelelser) fortsat:**

126

Røder MA, Kawa S, Scheike T, Toft BG, Hansen JB, Brasso K, Vainer B, Iversen P. Non-apical positive surgical margins after radical prostatectomy for pT2 prostate cancer is associated with the highest risk of recurrence. *J Surg Oncol* 2014; 109(8): 818-822

127

Berg KD, Thomsen FB, Hvarnæss H, Christensen IJ, Iversen P. Early biochemical recurrence, urinary continence, and potency outcomes following robot-assisted radical prostatectomy. *Scand J Urol*. 2014; 48(4): 356-66

128

Lippert SK, Iversen P, Brasso K, Goetze JP. C-type natriuretic peptide (CNP) and its precursor are new markers in prostate cancer. *Biomarkes in Medicine*, in press

129

Berg KD, Vainer B, Thomsen FB, Røder MA, Gerds TA, Toft BG, Brasso K, Iversen P. ERG protein expression in diagnostic specimens is associated with increased risk of progression during active surveillance for prostate cancer. *Eur Urol*. 2014; 66(5): 851-860

130

Ali Amin Al Olama, Kote-Jarai Z, Berndt SI, Conti D, Schumacher F, ....Iversen P,... Henderson BE, Easton DF, Eeles RE, Haiman CA.. A meta-analysis of 89,040 individuals identifies 23 novel susceptibility loci for prostate cancer. *Nature Genet* 2014; 46(10): 1103-1109

131

Beer TM, Armstrong AJ, Rathkopf DE, Loriot Y, Sternberg CN, Higano CS, Iversen P, Bhattacharya S, Carles J, Chowdhury S, Davis ID, de Bono JS, Evans CP, Fizazi K, Joshua AM, Choung-Soo K, Kimura G, Mainwaring P, Mansbach H, Miller K, Noonberg SB, Perabo F, Phung D, Saad F, Scher HI, Taplin M-E, Venner PM, Tombal B. Benefit of enzalutamide in chemotherapy-naïve metastatic prostate cancer. *N Engl J Med*. 2014; 371(5): 424-33.

132

Sveistrup J, Widmark A, Fransson P, Iversen P, Munck af Rosenschöld P, Engelholm SA, Pedersen PM. Prospective assessment of urinary, gastrointestinal and sexual symptoms before, during and after image-guided volumetric modulated arc therapy for prostate cancer. *Scand J Urol*. 2014 May 5. Epub ahead of print.

133

Thomsen FB, Berg KD, Røder MA, Brasso K, Iversen P. The burden of active surveillance for prostate cancer. *Scand J Urol*. Accepted for publication

134

Thomsen FB, Marcussen N, Berg KD, Iversen P, Christensen IJ, Vainer B, Brasso K. Repeated biopsies in prostate cancer patients on active surveillance: clinical implications of interobserver variation in histopathological assessment. *Br J Urol Int*. 2014 Jun 6. E-pub ahead of print.

135

Larsen SB, Brasso K, Christensen J, Tjønneland A, Friis S, Iversen P, Dalton SO. Influence of metabolic indicators and socioeconomic position on mortality after a prostate cancer diagnosis. *European Journal of Epidemiology*. Submitted

**Publikationer (originale meddelelser) fortsat:**

136

Kjærulff TM, Ersbøll AK, Green A, Emneus M, Pukkala E, Bolin K, Stavem K, Iversen P, Brasso K, Hallas J, Thygesen LC. Use of finasteride in the male populations of four Nordic countries: a cross-national drug utilization study. *British Journal of Clinical Pharmacology*, submitted.

137

Thomsen FB, Berg KD, Iversen P, Brasso K. Poor association between the progression criteria in active surveillance and subsequent histopathological findings following radical prostatectomy. *Br J Urol Int* - Submitted

**Publikationer (originale meddelelser – som medlem af co-operative grupper):**

138

Newling, D.W.W. on behalf of the European/Australian Co-operative Group: The response of advanced prostatic cancer to a new non-steroidal antiandrogen: Results of a multicenter open phase II study of Casodex. *European Urology* 18 (S3): 18-21, 1990.

139

Blackledge GRP, Andriole GL, Denis L, Blackledge G, Schmidt J, Sagalowsky A, Iversen P, Soloway M, Furr B, Block N, Banerjee T, Young J, Kolvenbag GCM, Oesterling JE, Nieh PTC, Montie JE, Schellhammer PF, Bales GT, Krauss D et al. High-dose bicalutamide monotherapy for the treatment of prostate cancer. *Urology* 47 (1 suppl A); 44-53, 1995

140

Prostate Cancer Trialists' Collaborative Group. Maximum androgen blockade in advanced prostate cancer: An overview of 22 randomised trials with 3283 deaths in 5710 patients. *Lancet* 346; 265-269, 1995.

141

Oesterling JE, Roy J, Agha A, Shown T, Krarup T, Johansen T, Lagerkvist M, Gormley G, Bach M, and Finasteride Study Group. Biologic variability of prostate-specific antigen and its usefulness as a marker for prostate cancer; effects of finasteride. *Urology* 1997; 50: 13-18.

142

Prostate Cancer Trialist's Collaborative Group. Maximum androgen blockade in advanced prostate cancer: an overview of randomised trials. *Lancet* 2000; 355: 1491-1498.

143

Newling DWW for the Maximum Androgen Blockade Case Study Group. Maximum androgen blockade: A case study report. *Prostate Cancer and Prostatic Diseases* 2000; 3: 203-212.

144

Spetz A-C., Hammar M, Lindberg B, Spångberg A, Varenhorst E, and the Scandinavian Prostatic Cancer Group-5 Trial Group. Prospective evaluation of hot flashes during treatment with parenteral estrogen or complete androgen ablation for metastatic carcinoma of the prostate. *Journal of Urology* 2001; 166: 517-520.

145

See WA, Tyrrell CJ, Casodex Early Prostate Cancer Trialist's Group. The addition of bicalutamide 150 mg to radiotherapy significantly improves overall survival in men with locally advanced prostate cancer. *J Cancer Res Clin Oncol* 2006; 132(suppl 1): S7-S16.

**Publikationer (oversigtsartikler):**

146

Iversen P, und die Dänische Prostatakrebsgruppe: Vergleichende Untersuchung von Goserelin Depot in Kombination mit Flutamid versus Orchiektomie in der Behandlung fortgeschrittener Prostatakarzinome. "Behandlung des fortgeschrittenen Prostatakarzinoms", 57-60. Eds: HGW Frohmüller und MP Wirth. Publisher. Springer-Verlag, 1990.

147

Iversen P. Is there a case for total androgen blockade? *Prog Clin Biol Res* 1990; 359: 109-115, 148

Iversen P. Discussion: Endocrine therapy - antiandrogens as monotherapy. *Prog Clin Biol Res* 1990; 359: 141-153.

149

Iversen P. Cancer prostatae. *Månedskrift for Praktisk Lægegering* 69; 633-644, 1991.

150

Iversen P. Behandlung des fortgeschrittenen Prostatakarzinoms -Studien der DAPROCA, der Dänischen Prostatakarzinomgruppe. In: *Aktuelle Diagnostik und Therapie des Prostatakarzinoms*. Ed.: R. Ackerman, J.E. Altwein, P. Faul. Springer-Verlag, Berlin-Heidelberg 1991, 394-404.

151

Iversen P, Wolf H. Classification. In: *Carcinoma of the prostate - views and recommendations*. Scandinavian Prostatic Cancer Group. Eds. Iversen P, Hedlund PO, Høisæter PÅ, Salo J. *Scand J Urol Nephrol* 25 (suppl 139): 5-9, 1991.

152

Iversen P. Staging and evaluation procedures. In: *Carcinoma of the prostate - views and recommendations*. Scandinavian Prostatic Cancer Group. Eds. Iversen P, Hedlund PO, Høisæter PÅ, Salo J. *Scand J Urol Nephrol* 25 (suppl 139): 19-24, 1991.

153

Iversen P. Response criteria. In: *Carcinoma of the prostate - views and recommendations*. Scandinavian Prostatic Cancer Group. Eds. Iversen P, Hedlund PO, Høisæter PÅ, Salo J. *Scand J Urol Nephrol* 25 (suppl 139): 31-38, 1991.

154

Iversen P. Prognostic factors. In: *Carcinoma of the prostate - views and recommendations*. Scandinavian Prostatic Cancer Group. Eds. Iversen P, Hedlund PO, Høisæter PÅ, Salo J. *Scand J Urol Nephrol* 25 (suppl 139): 39-42, 1991.

155

Iversen P. Early diagnosis - screening. In: *Carcinoma of the prostate - views and recommendations*. Scandinavian Prostatic Cancer Group. Eds. Iversen P, Hedlund PO, Høisæter PÅ, Salo J. *Scand J Urol Nephrol* 25 (suppl 139): 43-46, 1991.

146

Iversen P, Torp-Pedersen ST. Screening for prostatic cancer -sense or non-sense. *Current Opinion in Urology* 1: 4-7, 1991. Inviteret artikel.

157

Lorentzen T, Nerstrøm H, Iversen P, Torp-Pedersen ST. Local staging of prostatic cancer with transrectal ultrasound. A literature review. *The Prostate (suppl)* 4: 11-16, 1992.



**Publikationer (oversigtsartikler) fortsat:**

158

Torp-Pedersen ST, Iversen P. The case against screening for prostate cancer. *European Urology Update Series* 15: 114-119, 1993. Inviteret artikel..

159

Iversen P. Farmakologisk behandling af avanceret cancer prostatae. *Praktisk Lægemedelinformation* 10 årgang, nr.8, 1993. Inviteret artikel.

160

Iversen P, Adolfsson J, Johansson J-E, Torp-Pedersen S. Localized prostate cancer - A Scandinavian View. *Monographs in Urology* 15; 93-112, 1994. Inviteret artikel.

161

Iversen P. Screening for prostate cancer. The case against. *European Urology Today* 5; 15, 1995. Inviteret artikel.

162

Iversen P. Maximal androgen blockade - The Danish experience, In: *Sex Hormones and Antihormones in Endocrine Dependent Pathology: Basic and Clinical Aspects*. Eds.: Motta M and Sero M. *Excerpta Medica International Congress Series* 1064. ISBN: 0-444-81879-0. Elsevier Science B.V., Amsterdam 1994. pp 187-195. Inviteret artikel.

163

Kolvenbag GJCM, Blackledge G, Richie JP, Schellhammer PF, Scher H, Haas G, Patterson K, Sagalowsky A, Kennealey G, Iversen P, Brosman S, Klein EA, Block N, Denis L, Schmidt J, Soloway M. Worldwide activity and safety of bicalutamide: A summary review. *Urology* 47 (1 suppl A); 70-84, 1995.

164

Iversen P. Endocrine therapy - goals and limitations. In: Ed.: Fritz H. Schröder. *Recent Advances in Prostate Cancer and BPH. The Proceedings of the IV Congress on Progress and Controversies in Urological Oncology (PACIOU IV)*. Parthenon Publishing Group. 1997, 147-155. Inviteret artikel.

165

Graversen PH, Iversen P. Recent developments in endocrine therapy for prostate cancer I. *European Urology Update Series* 6; 40-43, 1997. Inviteret artikel.

166

Graversen PH, Iversen P. Recent developments in endocrine therapy for prostate cancer II. *European Urology Update Series* 6; 44-47, 1997. Inviteret artikel.

167

Iversen P. Scientific Highlights and Souvenirs from the XIIth Congress of the European Association of Urology - Prostate Cancer. *European Urology Today* 6; 2, 1996. Inviteret artikel.

168

Brasso K, Iversen P. Radikal prostatektomi for lokaliseret cancer prostatae. *Ugeskrift for Læger* 160; 4505-4509, 1998.

169

Iversen P, on behalf of the Scandinavian Prostatic Cancer Group. Combined androgen blockade in the treatment of advanced prostate cancer - an overview. *Scand J Urol Nephrol* 31; 249-254, 1997.

**Publikationer (oversigtsartikler) fortsat:**

170

Brasso K, Skaarup P, Roosen J, Iversen P. Anvendelse af prostataspecifikt antigen. En oversigt. Ugeskrift for Læger 160; 4510-4516, 1998.

171

Iversen P. Orchidectomy and oestrogen therapy revisited. Eur Urol 1998; 34(suppl.3): 7-11.

172

Iversen P. Antiandrogen Monotherapy. In: Eds. Kurth KH, Mickisch GH, Schröder FH. Renal, Bladder and Prostate Cancer – an Update. The Proceedings of the V Congress on Progress and Controversies in Urological Oncology (PACIOU V). Parthenon Publishing Group. London-New York 1999. P 183-190. Inviteret artikel.

173

Iversen P. Quality of life issues relating to endocrine treatment options. Eur Urol. 1999; 36 (suppl 2): 20-26.

174

McLeod D, Iversen P. Gynaecomastia in patients with prostate cancer: A review of treatment options. Urology 2000; 56: 713-720.

175

Brasso K, Iversen P. Prostatacancer. Hospital Health Care 2000; 2: 19-21.

176

Brasso K, Iversen P. Prostatacancer. Lægemagasinet 2000; 1: 33-35.

177

Iversen P, Melezinek I, Schmidt A. Nonsteroidal antiandrogens: a therapeutic option for advanced prostate cancer patients who wish to retain sexual interest and function. Br J Urol Int 2001; 87: 47-56.

178

Brasso K, Iversen P. The clinical utility of prostate specific antigen. Journal of Tumor Marker Oncology 2001; 16: 69-77.

179

Iversen P. Early versus delayed endocrine therapy. In: Eds. Kurth KH, Mickisch GH, Schröder FH. Renal, Bladder, Prostate and Testicular Cancer – an Update. The Proceedings of the VI Congress on Progress and Controversies in Urological Oncology (PACIOU VI). Parthenon Publishing Group. London-New York 2001; 137-147. Inviteret artikel.

180

Kolvenbag G, Newling D, Iversen P. Antiandrogen monotherapy: A new form of treatment for patients with prostate cancer. Urology 2001; 58 (2 suppl 1): 16-22.

181

Iversen P, Abrahamsson P-A, Mulders PFA. Advanced prostate cancer. European Urology 2001; 39/6 (Curriculum in Urology 1-10)

182

Kaisary AV, Iversen P, Tyrrell CJ, Carroll K, Morris T. Is there a role for antiandrogen monotherapy in patients with metastatic prostate cancer? Prostate Cancer and Prostatic Diseases 2001; 4: 196-203.

**Publikationer (oversigtsartikler) fortsat:**

183

Brasso K, Iversen P. Screening for Prostatocancer. Statusartikel. Ugeskrift for Læger 2002; 164: 155-157.

184

Iversen P. Antiandrogen monotherapy: Indications and results. Urology 2002; 60 (suppl 3A): 64-71

185

Iversen P, Newling D, Kirby R, Eardley I. Sexual function: Quality of life issues in patients with locally advanced non-metastatic prostate cancer. Eur Urol 2002; (suppl 1): 26-32

186

Iversen P. Bicalutamide monotherapy for early stage prostate cancer: An update. J Urol 2003; 170 (6) S48-S54.

187

Iversen P, Melezinek I, Schmidt A. Effects of endocrine therapy: - Can libido and sexual function be preserved? In: Eds. Bangma ChH and Newling DWW. Prostate and renal cancer, benign prostatic hyperplasia, erectile dysfunction and basic research. An update. The Parthenon Publishing Group, London. 2003. p 27-40

188

Iversen P. Radikal prostatektomi versus observation for lokaliseret prostatacancer. Ugeskrift for Læger 2003; 165: 139-140.

189

Iversen P. Current topics in the treatment of hormone-refractory prostate cancer. European Urology 2003 (Suppl 2): 3-8.

190

Carroll PR, Benaron DA, Blackledge G, Coakley FV, D'Amico AV, Higano CS, Iversen P, Kattan M, Nanus D, Nelson JB, Oh WK, Roach III M, Sellers WR, Smith MR, McManm MC, Kantoff PW. Third International Conference on Innovation and Challenges in Prostate Cancer: Prevention, Detection and Treatment. J Urology 2003; 170(6): S3-S5.

191

Djavan B, Zlotta A, Schulman C, Teillac P, Iversen P, Boccon Gibod L., Bartsch G, Marberger M. Chemotherapeutic prevention studies of prostate cancer. Journal of Urology 2004; 171 (2 pt.2) S10-13. Discussion S13-14.

192

Carroll PR, Chan JML, D'Amico AV, Gelmann EP, Iversen P, Klotz L, Nelson JB, Nelson PS, Nelson WG, Oh WK, Rosen N, Rubin MA, Sandler H, Sellers WR, Smith MR, Xu J, McManm M, Kantoff PW. Consensus Summary: Forth International Conference on Innovations and Challenges in Prostate Cancer: Prevention, Detection and Treatment. J Urol 2004; 172: S3-S5.

193

Iversen P. What are the benefits of adding bicalutamide (Casodex<sup>tm</sup>) to standard care for non-metastatic prostate cancer? Urologia Polska 2007; 60 (3): 179-183.

194

Borre M, Iversen P. Screening for prostatacancer – hvad siger evidensen? Ugeskrift for Læger 2007; 169: 1887-1888.

**Publikationer (oversigtsartikler) fortsat:**

195

Jakobsen H, Iversen P, Mikines KJ, Nørgaard N, Høyer M. Behandling af lokaliseret prostatacancer. Ugeskrift for Læger 2007; 169: 1902-1904.

196

Iversen P, Røder MA. The Early Prostate Cancer Program: Bicalutamide in nonmetastatic prostate cancer. Expert Rev Anticancer Ther 2008; 8: 361-369.

197

Iversen P, Røder AM. Diagnostik og behandling af prostatacancer. Rationel Farmakoterapi. Nr 9. September 2009.

198

Boccon-Gibod L, Iversen P, Persson B-E. Degarelix 240/80 mg: a new treatment option for patients with advanced prostate cancer. Expert Rev Anticancer Ther 2009; 9: 1737-1743

199

Iversen P. PSA baseret screening for prostatacancer. Klinisk Kemi i Norden 2011; 23: 10-15

200

Huber ML, Haynes L, Parker C, Iversen P. Interdisciplinary critique of Sipuleucel-T as immunotherapy in castration-resistant prostate cancer. JNCI (Journal of the National Cancer Institute) 2012; 104: 1-7.

201

Huber ML, Haynes L, Parker C, Iversen P. Response. JNCI (Journal of the National Cancer Institute) 2012 104: 1109-1112 (Debate about article above),

202

Røder MA, Iversen P. PSA screening for prostatacancer. Lægemedisinet 2012;5:14-16

203

Brasso K, Thomsen FB, Berg KD, Røder MA, Iversen P. Nye endocrine behandlinger forlænger overlevelsen ved kastrationsresistent prostatacancer. Ugeskrift for Læger 2013; 175 (40); 2328-2332

204

Thomsen FB, Brasso K, Klotz LH, Røder MA, Berg KD, Iversen P. Active surveillance for clinically localized prostate cancer – a systematic review. J Surg Oncol 2014; 109(8): 830-835

*Peter Iversen***Rapporter og betænkninger:**

205

Iversen P. Behandling af prostatacancer. In: SPRI Rapport 331: Prostatacancer i Norden. Praxis och ekonomi. Eds. Jonsson PM, Danneskiold-Samsøe B, Heggstad T. Stockholm 1992. p 25-36. Også publiceret i: Udredning og behandling af prostatacancer i Norden. Praxis og økonomi. Dansk Sygehus Institut. DSI-rapport 92.02, Copenhagen 1992

206

Crawford ED, Fourcade RO, Iversen P, Keuppens F, Khoury S, Labrie F, McConnell JD, Newling DWW, Schulze H. Management of newly diagnosed, metastatic prostate cancer. In Murphy G, Griffiths K, Denis L, Khoury S, Chatelain C, Cockett AT (eds). Report from First International Consultation on Prostate Cancer - patronized by WHO and UICC. Scientific Communication International Ltd, 1997. p 267-304.

207

Crawford ED, Boccon-Gibod L, Bruchovsky N, Iversen P, Kirk D, Kitamura T, Klein E, McKiel C, Labire F, McConnell JD, Vargas R. Management of newly-diagnosed metastatic prostate cancer. In: Murphy G, Khoury S, Partin A, Denis L (eds). Prostate Cancer – 2<sup>nd</sup> International Consultation on Prostate Cancer – patronized by WHO and UICC. Health Publication Ltd. Plymouth, United Kingdom. 2000; 351-394.

208

Iversen P, Rasmussen F, Mogensen P, Lundbeck F, Poulsen J, Roosen JU, Skaarup P, von der Maase H, Svanholm H. Prostatacancer. Betænkning fra arbejdsgruppe under Dansk Uro-Onkologisk Udvalg 1998. Klaringsrapport. Ugeskrift for Læger 1999; Suppl 4: 1-32.

210

Mommsen S, Brasso K, Graversen P, Iversen P, Jakobsen H, Ottosen P, Høyer M. Prostatacancerbetænkning 2005. [www.urologi.dk/rapporter/prostatacancer](http://www.urologi.dk/rapporter/prostatacancer)

211

Hart Hansen O, Laurberg S, Iversen P, Rasmussen PC, Roikjær O, Bisgaard C, Bülow S, Iversen LH, Brasholt M, Hammershøj E. Behandling af tarmkræft i Danmark – med fokus på den kirurgiske behandling. Sundhedsstyrelsen, August 2004.

212

Prostatacancer – Retningslinier 2012. [www.ducg.dk/prostata/retningslinier](http://www.ducg.dk/prostata/retningslinier)

**Ledere (editorials):**

213

Hedlund PO, Hugosson J, Iversen P. Är bot möjlig - Är bot nödvändig? NUF-Bulletinen, December 1994, 9-11. Inviteret artikel.

214

Iversen P. Prostatacancer. Ugeskrift for Læger 1997; 159: 2519. Inviteret leder.

215

Iversen P. Lokaliseret cancer prostatae "Min Mening". NUF Bulletinen, 11-12; December 1996 and Maj 1997. Inviteret artikel.

216

Iversen P. Prostatacancer. En sygdom med ny profil. Ugeskrift for Læger 1999; 161: 1241. Inviteret leder.

217

Iversen P. Introduction. In: Prostate Cancer: New Profiles, New Challenges. Editor: Iversen P. European Urology 2001; 39 (suppl 1): 1-2.

218

Iversen P. Quality of life issues in prostate cancer. Journal of Urology 2001; 166: 2291-2292. Invited editorial.

219

Iversen P. Metastaserende prostatacancer. Ugeskrift for Læger. 2003; 165: 2083. Inviteret leder.

220

Brasso K, Iversen P. Prostatacancer 2006 – Status og nye udfordringer. (Statusartikel). Ugeskrift for Læger 2006; 168: 1243.

221

Iversen P. Radikal prostatektomi er en etableret behandling for lokaliseret prostatacancer. NUF Bulletinen August 2006 (2): 15.

222

Borre M, Iversen P. Prinsen på kastanjen. Ugeskrift for Læger 2007; 169: 1881

223

Iversen P, Borre M, Andersen JR. Kritik af prostata-kampagnen. Ugeskrift for Læger 2008; 170: 2364.

224

Iversen P, Borre M, Andersen JR. Prostatacancer Patientforeningen PROPA – og oplysning om prostatakræft. Ugeskrift for Læger 2008; 170: 2897.

225

Iversen P. Prostate cancer in Denmark – personal reflexions. NUF Bulletinen 2009 (2): 18-20.

226

Iversen P and Brasso K. Diagnostik af prostatacancer. Transrektal biopsi. Ugeskrift for Læger. 2011; 173: 1783.

*Peter Iversen*

**Bogkapitler:**

227

Uehling DT, Iversen P. Urinary tract infections - female. "Current trends in Urology", 2: 114-131, 1982. Ed. M Resnick. Publisher: Williams and Wilkins Co., Baltimore Maryland, U.S.A.

228

Madsen PO, Iversen P. A point system for selecting operative candidates.

"Benign Prostatic Hypertrophy", 763-765, 1983.

Ed. F Hinman. Publisher: Springer-Verlag.

229

Iversen P, Torp-Pedersen ST, Holm HH. Prostatic carcinoma - Interstitiel radiotherapy.

"Prostatic Ultrasonography", 113-121, 1990.

Ed. M Resnick. Publisher: B.C. Becker Inc., Philadelphia, USA.

230

Iversen P, Torp-Pedersen ST. Screening for carcinoma of the prostate: Epidemiological and methodological aspects.

"Malignancies of the genito-urinary tract" in Recent Results in Cancer Research, 1993; 126: 1-24. Eds. Ackermann & Diehl. Publisher: Springer-Verlag

231

Iversen P. Cancer prostatae. "Cancer. Status over dansk onkologi. Klinisk del". Eds.:

Mouridsen H, Nordentoft AM, Rose C. Arkiv for Praktisk Lægegering, København 1993.

Page 110-121.

232

Nordling J med bidrag af Iversen P. Urinvejenes farmakologi. I "Basal og klinisk farmakologi" Eds.: Kampmann JP, Gram LF, Møhlholm Hansen J, Nielsen-Kudsk F, Schou JS. FADL's forlag, København 1994.

233

Iversen P, Høisæter PÅ, Rasmussen F. Cancer prostatae. I "Kirurgisk Kompendium". 2. udgave. Eds.: Hald T, Stadil F. Nyt Nordisk Forlag Arnold Busck, 1996, p 1585-1597.

234

Graversen P, Iversen P. Endocrine treatment - has it reached its limit? In: Questions and uncertainties about prostate cancer. Ed. Peeling WB. Blackwell Science Ltd., Oxford, 228-245, 1996.

235

Iversen P. Prostatacancer. Kapitel 247. I eds. Hald T, Lund B, Stadil F. Kirurgisk Kompendium Kittelbog. Nyt Nordisk Forlag Arnold Busck, 1999, p 321-322.

236

Iversen P, Pedersen KV, Abrahamsson P-A. Prostatacancer. I "Kirurgisk Kompendium". 3. udgave. Eds.: Stadil F, Lund B, Nordling J. Nyt Nordisk Forlag Arnold Busck, 2003, p 1372-1383

237

Iversen P. Prostatacancer. Kirurgisk Kompendium Kittelbog. 2. udgave. Eds. Stadil F, Lund B, Nordling. Nyt Nordisk Forlag Arnold Busck, 2006. Kapitel 245, side 342-343.

238

Iversen P, Kirkeby HJ. Urologi. Munksgaard Danmark. Basisbog i Medicin & Kirurgi. 3 udgave. Eds. Schrøder TV, Schultze S, Hilsted J, Gøtzsche L. 2007; 203-241.

**Bogkapitler (fortsat):**

239

Nordling J, Iversen P. Urinvejenes Farmakologi. I: Kampmann JP, Brøsen K, Simonsen U (eds): Basal og Klinisk Farmakologi. 3 udgave. Fagl's Forlag 2007. Kapitel 34; 443-449.

240

Nordling J, Iversen P. Urinvejenes farmakologi. I: Kampmann JP, Brøsen K, Simonsen U (eds): Basal og Klinisk Farmakologi. 4 udgave. Fagl's Forlag 2010. Kapitel 34; 434-439.

241

Iversen P, Kirkeby HJ. Urologi. Munksgaard Danmark. Basisbog i Medicin & Kirurgi. 4. udgave. Eds. Schrøder TV, Schultze S, Hilsted J, Gøtzsche L. 2011. Kapitel 8: 203-240

242

Iversen P. Prostatacancer. Kapitel 10.4.2. I eds. Svendsen LB, Nordling J, Dahl B, Hillingsø J. Kirurgisk Kompendium Kittelbog. 3. udgave. Nyt Nordisk Forlag Arnold Busck, 2011, p 360-362.

243

Iversen P, Kirkeby HJ. Urologi. Munksgaard Danmark. Basisbog i Medicin & Kirurgi. 5. udgave. Eds. Schrøder TV, Schultze S, Hilsted J, Gøtzsche L. 2012; 205-236.

244

Iversen P. Prostatacancer. I ed. Christoffer Johansen. Kræft - Senfølger og Rehabilitering. Hans Reitzels Forlag. 1. udgave 2013. p 30-45.



**Extended abstracts:**

1

Bruskewitz RC, Iversen P, Madsen PO. Predictive parameters in the surgical treatment of prostatism. Proceedings, 11th annual meeting. International Continence Society, 64-65, 1981.

2

Bruskewitz RC, Jensen KM-E, Iversen P, Madsen PO. The relevance of minimum urethral resistance in prostatism.

Proceedings, 12th annual meeting. International Continence Society 33-35, 1982.

3

Jensen KM-E, Bruskewitz RC, Iversen P, Madsen PO. Abdominal straining in benign prostatic hyperplasia.

Proceedings, 12th annual meeting. International Continence Society 186-187, 1982.

4

Iversen P, Nordling J, Boelt P, Iversen Hansen R.

Telemetric continuous monitoring of intravesical and rectal pressures.

Proceedings, 14th annual meeting. International Continence Society 384-385, 1984.

5

Iversen P, Hvidt V, Krarup T, Rasmussen F, Rose C, DAPROCA: Zoladex plus flutamide vs. orchiectomy in patients with advanced prostatic cancer - a phase III study.

Gynecol Endocrinol 2 (suppl. 1): 59-62, 1988.

6

Iversen P. Prostate cancer - results of two Danish trials - and future protocolled studies.

Proceedings, Finnish Urological Club, 22-30, 1989.

7

Iversen P. Is there a case for total androgen blockade?

Proceedings, Finnish Urological Club, 41-53, 1990.

8

Iversen P, Bak M, Juul N, Laursen F, von der Maase H, Nielsen L, Rasmussen F, Torp-Pedersen S, Holm HH. Ultrasonically guided 125-Iodine seed implantation with external radiation in management of localized prostatic carcinoma.

Key Interventional Radiology 1; 8-9, 1990.

9

Iversen P, and DAPROCA: Zoladex plus flutamide versus orchiectomy in the treatment of advanced prostatic cancer. Proceedings, 2nd International Symposium on GnRH Analogues in Cancer and Human Reproduction. 1990

10

Denis L, Iversen P, Suciú S, Christensen I, Sylvester R. and members of the EORTC-DAPROCA Group: Zoladex and flutamide versus orchidectomy - A combined analysis of two European studies. Proceedings. 2nd International Symposium on Recent Advances in Urological Cancer Diagnosis and Treatment. 1990.

11

Rocca-Rossetti S, Randone D, Zalcborg J, Kuber W, Lunglmaier G, Bouffieux C, Denis L, Keuppens F, Van Cangh PJ, Iversen P, Klarskov P, Alfthan O, Kontturi M, Permi J, Grasset D, Leduc A, Sarramon JP, Vallancien G, Altwein J et al. Studio aperta di fase II la valutazione della efficacia e della tollerabilita di Casodex (ICI 176,334), nuovo antiandrogeno non steroideo, nel trattamento del carcinoma prostatico avanzato. Acta Urol Ital 6 (suppl 4); 177-178, 1992.

**Extended abstracts (fortsat):**

12

Iversen P, Tveter K, Varenhorst E, and a Scandinavian Co-operative Group. Results of a Scandinavian multicenter open phase III study of Casodex versus orchidectomy in the treatment of metastatic prostatic carcinoma. Proceedings, Prostate Cancer, 3rd International Symposium on Recent Advances in Urological Cancer Diagnosis and Treatment. Eds.: Murphy G, Khoury S, Chatelain C, Denis L. Paris, 1992, page 120-125

13

Iversen P, on the behalf of the International Casodex Investigators. Update of monotherapy trials with the new anti-androgen, Casodex (ICI 176,334). Proceedings, 4th International Symposium on Recent Advances in Urological Cancer Diagnosis and Treatment. Eds.: Murphy G, Khoury S, Chatelain C, Denis L. Paris, 1994, page 317-323.

14

Iversen P. Endocrine Therapy - An Update. Proceedings, International Conference on Prostatic Carcinoma, Copenhagen; September 15-16, 1995. Eds. Abrahamsson P-A, Iversen P. Wells Medical Limited 1995, 37-42.

15

Fourcade RO, McLeod D, Iversen P, Wirth M, Cosaert J, Kolvenbag G, et al. Can hormonal treatment be beneficial for non-metastatic prostate cancer patients? Initiation of a world-wide study. Murphy G, Griffiths K, Denis L, Khoury S, Chatelain C, Cockett AT eds. Proc of the First Int Consult on Prostate Can. Scientific Communication Int Ltd., 1997; 267-303.

16

Iversen P, Kausary AV, Tyrrel C, Anderson J, Baert L, Tammela T, Chamberlain M, Webster A, Blackledge GRP. A randomised comparison of Casodex 150 mg versus castration in the treatment of advanced prostate cancer. British Journal of Urology, 80 (suppl 2); 279, 1997.

17

Iversen P. Monotherapy versus total androgen blockade in the management of advanced prostate cancer. In ed. Schröder FH. Prostate Cancer. Epidemiology, prevention and endocrine treatment. Proceedings, An ESU-organized symposium, in cooperation with the Hungarian Urological Association, Budapest, Hungary. The Parthenon Publishing Group, New York, London, 40-42, 1998.

*Peter Iversen*

**Andre publikationer:**

Steven K, Iversen P. Kirurguddannelsen i Danmark - er bunden nået? Dansk Kirurgisk Selskab - Nyhedsbrev 48; 11, 1993

Iversen P, Steven K. Kirurguddannelsen i krise. Ugeskrift for Læger 155; 4118, 1993

Iversen P. Kræft i blærehalskirtlen. Helse 36: 38-39, 1990

Kræft i blærehalskirtlen. Sygdommens og dens behandling.  
Informationspjece fra Kræftens Bekæmpelse 1994.  
Medforfatter og sagkyndigt medlem af redaktionen.

Iversen P. Rapport fra SPCG. NUF bulletinen. Sommer 1998; 15-16.

Skal radikal prostatektomi indføres? Kommentar af Peter C. Gøtzche med svar af Peter Iversen. Ugeskrift for Læger 1999; 161: 3472-3274.

Radikal prostatektomi er udokumenteret. Kommentar af Peter C. Gøtzche med svar af Peter Iversen. Ugeskrift for Læger 1999; 161: 5691-5692

Iversen P, Stimpel H. Kursus i Operativ Kirurgi – Urologi. Kursusbog til A-kursus i operativ kirurgi. Gennemgående revision af oplæg forfattet af Troels Munch Jørgensen. 2001.

Iversen P. Nye præparater til behandling af fremskreden prostatakræft. PROPA (Prostatacancer patientforeningen). Nyhedsbrev, November 2002.

See W, Iversen P, Wirth M, McLeod D, Morris T. Reply to A Tubaro and C de Nunzio. Eur Urol 2004; 45(5): 674-675.

Gråzone-screening for prostatacancer. Kommentar af Ulrik Dige med svar af Peter Iversen. Ugeskrift for Læger 2004; 50:

Iversen P. Spørg Riget: Langsom og harmløs – eller hurtig og aggressiv. Politiken(artikelserie). 27.5.2005.

M. Andreas Røder; Peter Iversen: Diagnostik og behandling af prostatacancer. Lægemagasinet, september 2010.

Iversen P, Bagi P, Brasso K, Andersen JR, Jakobsen H, Johansen J, Graverson P, Langkilde NC. Kryobehandling af prostatacancer. Ugeskrift for Læger 2011; 173: 1080

Brasso K, Iversen P. Kommentar til statusartikel om Denosumab. Ugeskrift for Læger 2011; 173: 677

Iversen P, Bagi P, Brasso K, Andersen JR, Jakobsen H, Johansen J, Graverson P, Langkilde NC. Kryobehandling af prostatacancer II. Ugeskrift for Læger 2011; 173: 1748

*Peter Iversen***Andre publikationer (fortsat):**

Iversen P, Thomsen FB, Berg KD. Kommentar til: "Tardivt respons eller miraklernes tid". Ugeskrift for Læger 2012; 174: 2811

Iversen P. Overbehandling – Fup eller Fakta? PROPANYT (Udgivet af Prostatakræftforeningen). Februar 2013; 1: 18-20.

**Redaktionelle opgaver:**

Carcinoma of the prostate - views and recommendations. Scandinavian Prostatic Cancer Group. Eds. Iversen P. (first editor) Hedlund PO, Høisæter PÅ, Salo J. Scand J Urol Nephrol 25 (suppl 139) 1991.

Proceedings. International Conference on Prostatic Carcinoma. Copenhagen, September 15-16, 1995. Eds. Abrahamsson P-A and Iversen P. Wells Medical Limited 1995.

Proceedings. 2nd International Prostate Cancer Meeting, Copenhagen, August 23-24, 1997. Eds. Abrahamsson P-A and Iversen P. Wells medical Limited 1997.

Prostate Cancer: New Profiles, New Challenges. Editor: Iversen P. European Urology 2001; 39 (suppl 1): 1-28.

**Bog anmeldelser:**

Parkinson J. A manual of English for the overseas doctor. Ugeskr for Læger 147: 3855, 1985.

Vanggaard L. Ny lægebog for søfarende. Ugeskrift for Læger 149: 2615, 1987.

